The Panels Complete Bio-Rad’s Set of Bio-Plex™ Pro Multiplex
SARS-CoV-2 Human Serology Panels for Detection of Antibodies Against
Four SARS-CoV-2 Antigens

HERCULES, Calif.–September 30, 2021–Bio-Rad Laboratories, Inc.
(NYSE: BIO and BIOb), a global leader of life science research and
clinical diagnostic products, today announced the launch of the
Bio-Plex™ Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and
IgM antibodies against four SARS-CoV-2 antigens. The panels are for
research use only (RUO).

The Bio-Plex Pro Human IgA SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel and the
Bio-Plex Pro Human IgM SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel join
Bio-Rad’s existing Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2
4-Plex Panel to complete the set of three separate qualitative multiplex
immunoassays that provide precise and efficient detection of IgA, IgG,
and IgM antibodies against four SARS-CoV-2 antigens. The panels assist
researchers in developing vaccines, and the panels also help public
health researchers who perform seroprevalence studies based on serology
specimens to identify individuals who may have been exposed to
SARS-CoV-2. These individuals may have not been diagnosed with COVID-19
and could have experienced only mild symptoms, or they could be
asymptomatic.

“The multiplex immunoassay panels help vaccine developers determine
therapeutic efficacy, from development through clinical phases and then
later on in postmarket surveillance studies,” said Candice Cox,
Bio-Rad Immunoassays Marketing Manager, Life Science Group. “Detecting
levels of antibodies against SARS-CoV-2 in an individual provides
valuable information about possible exposure rates in a population or
about the effectiveness of COVID-19 vaccines in preventing the spread of
this disease,” she said.

About the Bio-Plex Pro Human SARS-CoV-2 Serology Panels

The Bio-Plex Pro Human IgA, IgG, and IgM SARS-CoV-2 panels are three
separate ready-to-use 96-well kits containing premixed magnetic capture
beads, an isotype-specific detection antibody, positive and negative
controls, and buffers, to produce results for four anti–SARS-CoV-2
antibodies. Individual components such as viral antigen–coupled beads
are offered as singleplex assay reagents for multispecies assay
development that enables measurement of antibodies against specific
viral antigens of interest while improving research laboratory
efficiency.

Key Benefits

*
Can be provided as a kit that includes all required reagents
*
Help researchers simultaneously profile antibodies against four
SARS-CoV-2 viral antigens: the nucleocapsid protein (N) and the receptor
binding domain (RBD), and the spike 1 (S1) and spike 2 subunits (S2) of
the spike protein
*
Provide results in less than 3 hours
*
Enable comparison of median fluorescence intensity (MFI) values of
samples to help researchers and vaccine developers understand the
strength of response and antibody levels at different time points after
SARS-CoV-2 infection or vaccination

Please visit bio-rad.com/Bio-PlexCOVIDAbs [1] for more information.

_ _

_BIO-RAD and BIO-PLEX are trademarks of Bio-Rad Laboratories, Inc. in
certain jurisdictions. The Bio-Plex Suspension Array System includes
fluorescently labeled microspheres and instrumentation licensed to
Bio-Rad Laboratories, Inc. by the Luminex Corporation. All trademarks
used herein are the property of their respective owner.__ ___

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in
developing, manufacturing, and marketing a broad range of innovative
products for the life science research and clinical diagnostic markets.
With a focus on quality and customer service for over 65 years, our
products advance the discovery process and improve healthcare. Our
customers are university and research institutions, hospitals, public
health and commercial laboratories, biotechnology and pharmaceutical
companies, as well as applied laboratories that include food safety and
environmental quality. Founded in 1952, Bio-Rad is based in Hercules,
California, and has a global network of operations with approximately
7,700 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion
in 2020.